We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $297 · 5 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
A Look at Bio-Rad Laboratories Inc (BIO) After 4.2% Gain -- GF V - GuruFocus
A Look at Bio-Rad Laboratories Inc (BIO) After 4.2% Gain -- GF V GuruFocus
[144] BIO-RAD LABORATORIES, INC. SEC Filing - Stock Titan
[144] BIO-RAD LABORATORIES, INC. SEC Filing Stock Titan
How Investors May Respond To Bio-Rad Laboratories (BIO) Facing Elliott’s Activist Push Over Sartorius Stake - simplywall.st
How Investors May Respond To Bio-Rad Laboratories (BIO) Facing Elliott’s Activist Push Over Sartorius Stake simplywall.st
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $1.75 | — | — | $623.99M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $2.29 | — | — | $585.4M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-39.89 | — | — | $1.9B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-62.61 | — | — | $1.25B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 01. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2026. 04. 07. | Citigroup | — | Downgrade | Buy → Neutral | — | Citigroup: Buy → Neutral |
| 2026. 02. 17. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2025. 10. 31. | Citigroup | — | Maintain | Buy → Buy | — | Citigroup: Buy |
| 2025. 10. 30. | Wells Fargo | — | Maintain | Equal-Weight → Equal-Weight | — | Wells Fargo: Equal-Weight |
| 2025. 08. 02. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.